In animal and lab studies, yes. AKBA, the lead boswellic acid, suppressed MMP13 in rats with chemically induced knee damage, and a frankincense extract lowered MMP13 gene activity in cartilage samples. Human trials of boswellia extracts measured other markers, such as MMP-3 and collagen breakdown fragments, not MMP13 itself.
Abo-Zalam and colleagues injected a chemical, monosodium iodoacetate, into the right knees of male rats to damage the joint, then gave AKBA by mouth daily from day 3 to day 14, with nine rats per group (Abo-Zalam 2025). AKBA suppressed MMP13 and raised TIMP-1, the body's own MMP brake, and SOX9, a cartilage-building control protein. It lowered CTX-II, a fragment of type II collagen, in the blood, and the cartilage scores returned to normal (Abo-Zalam 2025). It also calmed the HMGB1, TLR4 and NF-kB inflammatory pathway and raised the Nrf2 antioxidant pathway. The abstract labels the treated group AKBA250 without spelling out the unit.
Blain and colleagues broke down cartilage samples over 28 days with two inflammatory messengers, IL-1 alpha and oncostatin M, with or without 100 micrograms per ml of a Boswellia frereana extract (Blain 2010). The extract stopped the breakdown of the collagen matrix and reduced MMP9 and MMP13 mRNA. Its main constituent turned out to be epi-lupeol rather than a boswellic acid (Blain 2010). Boswellia frereana is a different species from Boswellia serrata, the one used in most trials.
In rats with chemically induced knee damage, 5-Loxin, a Boswellia serrata extract, given by mouth, preserved glycosaminoglycans and aggrecan in the joint by turning down MMPs (Shin 2022). The abstract reports MMPs as a group and doesn't single out MMP13.
Four placebo-controlled trials in people with knee osteoarthritis have tested boswellia extracts:
None of these abstracts reports measuring MMP13. MMP-3 is a different MMP, and CTX-II shows collagen breakdown without naming the enzyme responsible.
The MMP13 evidence for boswellia comes from rats and cartilage samples (Abo-Zalam 2025; Blain 2010). The human trials each tested one extract at one dose, and their results belong to those extracts. They don't show what other boswellia preparations, other doses or combinations would do.
3-O-acetyl-11-keto-beta-boswellic acid, the lead boswellic acid in boswellia resin. In rats it suppressed MMP13 and raised the MMP inhibitor TIMP-1.
Frankincense comes from Boswellia trees. The cartilage sample study used Boswellia frereana; most human trials used extracts of Boswellia serrata.
Not according to their abstracts. They measured MMP-3 and type II collagen breakdown fragments such as CTX-II.
In lab and animal studies, yes. Curcumin lowered MMP13 in rat cartilage cells exposed to IL-1 beta, and a curcumin metabolite bound and blocked MMP13 directly and...
In two main ways. Cells release MMP13 as an inactive proenzyme that must be cut before it works, and the body makes its own inhibitors, the TIMPs. TIMP-1, TIMP-2 and...
Its collagen barely does, on most measurements. Radiocarbon dating of knee cartilage from 23 people found virtually no replacement of the collagen network after the...
Type II collagen is the main collagen in joint cartilage. Collagen makes up about two-thirds of adult cartilage's dry mass, and type II is its principal molecule, woven...